Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
"HIV Preventive Vaccine" [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months
Condition: HIV Infections
Intervention: Biological: rgp120/HIV-1 SF-2
3 Withdrawn Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP;   Biological: Vaccine placebo
4 Completed Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults
Condition: HIV Infections
Intervention: Biological: HIV DNA plasmid vaccine plus recombinant fowlpox vector
5 Completed Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-B;   Biological: IL-12 DNA plasmids
6 Completed Development of a New HIV Vaccine
Condition: HIV Infections
Intervention: Biological: PolyEnv1
7 Completed A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
8 Completed A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (MicroGeneSys)
9 Withdrawn Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP;   Biological: VRC-HIVDNA016-00-VP placebo;   Biological: VRC-HIVADV014-00-VP placebo
10 Active, not recruiting Antigenic Competition in HIV Preventive Vaccines
Condition: HIV Infections
Interventions: Biological: rAd5 Gag-Pol Env A/B/C;   Biological: rAd5 Gag-Pol
11 Completed A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
Condition: HIV Infections
Interventions: Biological: APL 400-047;   Biological: ALVAC-HIV MN120TMG (vCP205);   Drug: Sargramostim
12 Completed Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa
Condition: HIV Infections
Interventions: Biological: AVX101;   Other: placebo
13 Completed Analysis of Immune Responses to HIV Vaccines
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention:
14 Completed Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV
Conditions: HIV Infections;   H1N1 Influenza
Intervention: Biological: Arepanrix
15 Completed Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
Condition: HIV Infections
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: gp160 MN/LAI-2;   Biological: ALVAC(1)120(B,MN)GNP (vCP1433);   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65)
16 Completed Screening Protocol for HIV Vaccine Studies
Conditions: HIV Seronegativity;   HIV Infections
Intervention:
17 Completed A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: APL 400-047;   Drug: Bupivacaine hydrochloride
18 Completed A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)
Condition: HIV Infections
Interventions: Biological: TBC-3B Vaccine;   Biological: Smallpox Vaccine
19 Completed A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
20 Completed A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV MN120TMG (vCP205)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years